Delivery Order SPE2DB22D3501-SPE2DB25FWP52
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,522.97 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order, awarded on July 25, 2025, represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,279.87 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count package) on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, on July 29, 2025. The contract, valued at approximately $12.1K, is for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price arrangement. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Gemtesa 75 mg tablets (30-count packages) with a contract ceiling value of $4,316.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $16,491.74. This firm fixed-price delivery order, which is due for completion by July 22, 2025, represents a pharmaceutical supply requirement under DLA's medical procurement operations. The award was competitively awarded with no set-aside designation, and AmerisourceBergen will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) valued at $7,179.96. This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a delivery order, this award represents a single fulfillment action under a larger contracting vehicle...
- The Defense Logistics Agency awarded a $10,584.22 delivery order to AmerisourceBergen Drug Corp for 90-count bottles of Gemtesa 75 mg tablets, with performance in Conshohocken, Pennsylvania and a completion deadline of July 31, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,840.51 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a $7,983.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, where the pharmaceutical products will be delivered. The contract represents a routine pharmaceutical procurement supporting federal medical supply requirements,...
- The Defense Logistics Agency awarded a $3,493.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of August 4, 2025. This non-competitive delivery order, issued on August 1, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical....
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWP52Delivery Order
The Defense Logistics Agency (DLA) awarded a $2,757.50 delivery order to AmerisourceBergen Drug Corp for 90-tablet containers of Gemtesa 75 mg on July 25, 2025, with completion targeted for July 28, 2025. This competitive award, issued without set-aside designation, is structured as a firm fixed price delivery order and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is the vendor's corporate office in Conshohocken, Pennsylvania, positioning the pharmaceutical distributor to fulfill federal medical procurement requirements for military and veteran healthcare systems. This delivery order falls under AmerisourceBergen Drug Corp's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen leverages this prime contract vehicle to supply brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs globally. The company's extensive portfolio of federal contract awards demonstrates its capacity to meet DLA's diverse pharmaceutical procurement needs across competitive delivery orders ranging from minimal to substantial values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 7/25/25 |